CDK1 and glioma: Hayashi et al. found increased DNA repair activity in the G2-M transition promoted temozolomide (TMZ) resistance and CDC2 inhibitor flavopiridol (FP) treatment could resensitize TMZ-resistant clones in a p53-independent manner in glioma cells [44].